[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Gary Pace Biography and Net Worth

Director of Cardiff Oncology

Gary Pace has been a director since 2020. He has been a director of Pacira Biosciences, Inc. since 2008, Simavita Ltd. since 2016 and Antisense Therapeutics since 2015 as well as a director of several private companies. Dr. Pace previously served on the board of ResMed Inc. from 1994 to 2018, Transition Therapeutics Inc. from 2002 to 2016 and ORxPharma Ltd. from 2001 to 2013. He is a seasoned biopharmaceutical executive with over 40 years of experience in the industry. He as co-founded several early-stage life science companies, where he built products from the laboratory to commercialization. Dr. Pace has contributed to the development of the biotechnology industry through honorary university appointments and industry and government committees. In 2003, he was awarded a Centenary Medal by the Australian Government “for service to Australian society in research and development” and was recognized as the 2011 Director of the Year (corporate governance) by the San Diego Directors Forum. Dr. Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D. from the Massachusetts Institute of Technology where he was a Fulbright Fellow and General Foods Scholar. The Board believes that Dr. Pace’s years of experience providing strategic advisory services to complex organizations, including as a public company director provides him with the qualifications and skills to serve as a director.

What is Gary W. Pace's net worth?: The estimated net worth of Gary W. Pace is at least $57,087.66 as of March 8th, 2024. Dr. Pace owns 22,127 shares of Cardiff Oncology stock worth more than $57,088 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Pace may own. Learn More about Gary W. Pace's net worth.
How do I contact Gary W. Pace?: The corporate mailing address for Dr. Pace and other Cardiff Oncology executives is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. Cardiff Oncology can also be reached via phone at (858) 952-7570 and via email at [email protected]. Learn More on Gary W. Pace's contact information.
Has Gary W. Pace been buying or selling shares of Cardiff Oncology?: Gary W. Pace has not been actively trading shares of Cardiff Oncology during the last ninety days. Most recently, on Tuesday, December 19th, Gary W. Pace bought 30,000 shares of Cardiff Oncology stock. The stock was acquired at an average cost of $1.37 per share, with a total value of $41,100.00. Following the completion of the transaction, the director now directly owns 697,761 shares of the company's stock, valued at $955,932.57. Learn More on Gary W. Pace's trading history.
Who are Cardiff Oncology's active insiders?: Cardiff Oncology's insider roster includes John Brancaccio (Director), Mark Erlander (CEO), Vicki Kelemen (COO), James Levine (CFO), Rodney Markin (Director), and Gary Pace (Director). Learn More on Cardiff Oncology's active insiders.
Are insiders buying or selling shares of Cardiff Oncology?: In the last year, Cardiff Oncology insiders bought shares 1 times. They purchased a total of 30,000 shares worth more than $41,100.00. The most recent insider tranaction occured on December, 19th when Director Gary W Pace bought 30,000 shares worth more than $41,100.00. Insiders at Cardiff Oncology own 7.8% of the company. Learn More about insider trades at Cardiff Oncology.
Information on this page was last updated on 12/19/2023.

Gary W. Pace Insider Trading History at Cardiff Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/19/2023	Buy	30,000	$1.37	$41,100.00	697,761
9/21/2021	Buy	30,000	$6.75	$202,500.00
3/18/2021	Buy	3,000	$10.55	$31,650.00	452,811
3/4/2021	Buy	1,500	$9.27	$13,905.00	451,811
9/16/2020	Buy	2,550	$5.70	$14,535.00	449,461

Gary W. Pace Buying and Selling Activity at Cardiff Oncology

Cardiff Oncology Company Overview

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $2.58

$2.46

$2.59

50 Day Range

MA: $2.84

$2.46

$4.09

2 Week Range

Now: $2.58

$1.13

$6.42

Volume

218,572 shs

Average Volume

944,490 shs

Market Capitalization

$131.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.93

Man behind OpenAI makes shocking new bet

From DTI | Ad

Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.

Check out our report right here.